285. Fanconi anemia
56 clinical trials,   111 drugs   (DrugBank: 31 drugs),   30 drug target genes,   151 drug target pathways

Searched query = "Fanconi anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04483544
(ClinicalTrials.gov)
August 10, 202020/7/2020Pembrolizumab and Olaparib in Cervical Cancer PatientsImmunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair PathwayCervical Cancer;Cervical CarcinomaDrug: pembrolizumab;Drug: olaparibBaptist Health South FloridaFlorida Department of Health;Merck Sharp & Dohme Corp.Recruiting18 YearsN/AFemale48Phase 2United States
2NCT04042831
(ClinicalTrials.gov)
June 9, 202029/7/2019Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsA Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsARID1A Gene Mutation;ATM Gene Mutation;ATR Gene Mutation;Bile Duct Adenocarcinoma;BRCA1 Gene Mutation;BRCA2 Gene Mutation;BRIP1 Gene Mutation;CHEK2 Gene Mutation;EMSY Gene Mutation;Fanconi Anemia Complementation Group Gene Mutation;Metastatic Bile Duct Carcinoma;MRE11 Gene Mutation;NBN Gene Mutation;PALB2 Gene Mutation;PTEN Gene Deletion;RAD51 Gene MutationDrug: OlaparibAcademic and Community Cancer Research UnitedNational Cancer Institute (NCI)Recruiting18 YearsN/AAll36Phase 2United States